A Agilent Technologies Inc.

Agilent Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research

(NYSE: A) announces the new . This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all skill levels. With this cost-effective and versatile kit, researchers can easily incorporate functional assessment of relative mitochondrial respiration into their cell physiology and disease pathology studies.

Mitochondria are central to energy production processes that drive cellular activity, and mitochondrial dysfunction is linked to numerous diseases and conditions. The Mito-rOCR assay enables more researchers to explore this crucial aspect of biology with accuracy and ease. The assay can be used with various compatible fluorescent plate readers and multimode imagers that meet its requirements for sensitivity, detection capabilities, and environmental control.

For example, the BioTek Cytation series of fluorescence plate readers and multimode imagers are ideal for the Mito-rOCR assay. Their advanced software allows them to handle various applications, maintain optimal conditions, and automate processes, making them reliable and adaptable for different research needs.

The Mito-rOCR assay measures cells’ relative oxygen consumption rate (rOCR), enabling sensitive detection of changes in mitochondrial function. This approach offers thorough insights into mitochondrial health and performance. With the Mito-rOCR Assay Kit, compounds are reconstituted directly in the assay medium, eliminating the need for additional solvents.

Notably, the assay is also reversible; the reagent remains outside the cells to prevent interference with cellular processes and can be easily removed to allow further downstream analyses. Data analysis is conducted using the Mito-rOCR Analysis Module within . This cloud-based software makes importing data, linearizing signals, calculating slopes, and generating data tables and bar charts easy and streamlined.

Chris Braun, associate vice president of Marketing in Agilent’s Cell Analysis Division, commented on the importance of this announcement. “The Agilent Mito-rOCR Assay Kit was developed in direct response to customer feedback, as they told us they needed an easy-to-use assay that works with various fluorescence plate readers. The Mito-rOCR Assay Kit delivers this with a robust assay that supports multiplexing. This innovative assay democratizes the measurement of relative oxygen consumption rate in live cells, enabling more researchers to study cellular respiration and related biological processes.”

A key part of Agilent’s family of metabolic analysis solutions, the Mito-rOCR Assay Kit further expands Agilent’s broad range of uniquely enabling tools for interrogating cellular metabolism. These tools deliver a functional view of cell metabolism to more scientists, facilitating scientific advancement and accelerating discovery across critical areas of biological investigation.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
14/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

 PRESS RELEASE

Agilent Presents Solutions Innovation Research Awards to Aarhus Univer...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of , Professor Walter Gössler of , and Professor Gregory Offer of . These separate awards recognize their outstanding contributions to battery research. Developing new materials for more efficient and durable batteries is essential to reducing fossil fuel reliance and meeting global energy storage needs. Given the limited supply of critical metals like lithium, it is crucial to focus on pioneering new materials and recovering and reusin...

 PRESS RELEASE

Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conferenc...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time. A live audio webcast and replay of the presentation will be available on the . About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full ran...

 PRESS RELEASE

Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives Eur...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Agilent’s PD-L1 IHC 28-8 pharmDx (Code SK005) provides clinically relevant information about PD-L1 expression – a critical biomarke...

 PRESS RELEASE

Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023. Fourth-quarter GAAP net income was $351 million, or $1.22 per share. This compares with $475 million, or $1.62 per share, in the fourth quarter of fiscal year 2023. Non-GAAP(2) net income was $418 million, or $1.46 per share during the quarter, compared with $404 million or $1.38 per share during the fourth quarter a year ago. “The A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch